Methods and products for transfecting cells

Patent metadata

Field	Value
Publication number	US-11708586-B2
Application number	US-202016913315-A
Country	US
Kind code	B2
Filing date	Jun 26, 2020
Priority date	Dec 5, 2011
Publication date	Jul 25, 2023
Grant date	Jul 25, 2023

Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

First claim

What is claimed is:

1. A method for producing a gene-edited cell, comprising:
(a) culturing a human non-pluripotent cell comprising a target DNA sequence; and
(b) transfecting the cell with a plurality of synthetic RNA molecules, wherein the synthetic RNA molecules include:
i. a first synthetic RNA molecule encoding a first fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease; and
ii. a second synthetic RNA molecule encoding a second fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease;
wherein:
the first fusion protein and the second fusion protein are independently a transcription activator-like effector nuclease (TALEN);
the transfecting results in the cell expressing the first fusion protein and the second fusion protein to result in a single-strand break or a double-strand break in the target DNA sequence; and
the first synthetic RNA molecule and the second synthetic RNA molecule are independently synthesized by in vitro transcription from a DNA template.

2. The method of claim 1 , further comprising contacting the cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

3. The method of claim 1 , further comprising contacting the cell with a medium.

4. A method for producing a gene-edited cell comprising an inserted DNA sequence, comprising:
(a) culturing a human non-pluripotent cell comprising a target DNA sequence;
(b) transfecting the cell with a plurality of synthetic RNA molecules, wherein the synthetic RNA molecules include:
i. a first synthetic RNA molecule encoding a first fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease; and
ii. a second synthetic RNA molecule encoding a second fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease;
wherein the first fusion protein and the second fusion protein are independently a transcription activator-like effector nuclease (TALEN), the transfecting results in the cell expressing the first fusion protein and the second fusion protein to result in a single-strand break or a double-strand break in the target DNA sequence; and wherein the first synthetic RNA molecule and the second synthetic RNA molecule are independently synthesized by in vitro transcription from a DNA template; and

(c) transfecting the cell with a DNA repair template comprising a sequence for insertion and one or more regions of homology to the DNA of the cell, wherein the one or more regions of homology comprise regions upstream and/or downstream of the single-strand break or the double-strand break, to result in insertion of the sequence in the region of the single-strand break or the double-strand break.

5. The method of claim 4 , further comprising contacting the cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

6. The method of claim 4 , further comprising contacting the cell with a medium.

7. The method of claim 1 , wherein the human non-pluripotent cell is a skin cell or a hematopoietic cell.

8. The method of claim 7 , wherein the hematopoietic cell is a hematopoietic stem cell or a white blood cell.

9. The method of claim 8 , wherein the skin cell is obtained from a biopsy.

10. The method of claim 7 , wherein the skin cell is a fibroblast, a keratinocyte, a melanocyte, an adipocyte, a mesenchymal stem cell, an adipose stem cell, or a blood cell.

11. The method of claim 1 , wherein the plurality of synthetic RNA molecules are complexed with a transfection reagent.

12. The method of claim 11 , wherein the transfection reagent is lipid-based, polymer-based, or peptide-based.

13. The method of claim 12 , wherein the transfection reagent comprises a charged polymer or a cell-penetrating peptide.

14. The method of claim 12 , wherein the transfection reagent comprises a cationic lipid, a liposome, or a micelle.

15. The method of claim 3 , wherein the medium is substantially free of immunosuppressants.

16. The method of claim 1 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule comprise at least one non-canonical nucleotide selected from the group consisting of: a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5-hydroxypseudouridine residue, and a 5-methylcytidine residue.

17. The method of claim 1 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule further comprise one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

18. The method of claim 4 , wherein the human non-pluripotent cell is a skin cell or a hematopoietic cell.

19. The method of claim 18 , wherein the hematopoietic cell is a hematopoietic stem cell or a white blood cell.

20. The method of claim 18 , wherein the skin cell is obtained from a biopsy.

21. The method of claim 18 , wherein the skin cell is a fibroblast, a keratinocyte, a melanocyte, an adipocyte, a mesenchymal stem cell, an adipose stem cell, or a blood cell.

22. The method of claim 4 , wherein the plurality of synthetic RNA molecules are complexed with a transfection reagent.

23. The method of claim 22 , wherein the transfection reagent is lipid-based, polymer-based, or peptide-based.

24. The method of claim 23 , wherein the transfection reagent comprises a charged polymer or a cell-penetrating peptide.

25. The method of claim 23 , wherein the transfection reagent comprises a cationic lipid, a liposome, or a micelle.

26. The method of claim 6 , wherein the medium is substantially free of immunosuppressants.

27. The method of claim 4 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule comprise at least one non-canonical nucleotide selected from the group consisting of: a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5-hydroxypseudouridine residue, and a 5-methylcytidine residue.

28. The method of claim 4 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule further comprise one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

29. The method of claim 4 , wherein the DNA repair template comprises one or more regions of homology to the DNA of the cell upstream or downstream of the single-strand break or the double-strand break.

30. The method of claim 29 , wherein the DNA repair template comprises one or more regions of homology to the DNA of the cell upstream of the single-strand break or the double-strand break.

31. The method of claim 29 , wherein the DNA repair template comprises one or more regions of homology to the DNA of the cell downstream of the single-strand break or the double-strand break.

32. The method of claim 4 , wherein the DNA repair template comprises one or more regions of homology to the DNA of the cell upstream and downstream of the single-strand break or the double-stra

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• H10F19/80

  Encapsulations or containers for integrated devices, or assemblies of multiple devices, having photovoltaic cells · CPC title

• C12Q1/6806

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title

• C12N15/87 Primary

  Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C08K5/5399 Primary

  Phosphorus bound to nitrogen · CPC title